IRIS
BRILLANTI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.641
EU - Europa 2.983
AS - Asia 1.585
SA - Sud America 435
AF - Africa 33
OC - Oceania 5
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.684
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.570
GB - Regno Unito 719
RU - Federazione Russa 667
CN - Cina 564
IE - Irlanda 530
SG - Singapore 501
BR - Brasile 379
IT - Italia 370
FR - Francia 216
HK - Hong Kong 190
UA - Ucraina 142
VN - Vietnam 132
SE - Svezia 121
DE - Germania 72
FI - Finlandia 46
CA - Canada 37
KR - Corea 37
IN - India 30
TR - Turchia 28
AR - Argentina 24
MX - Messico 23
BD - Bangladesh 16
NL - Olanda 16
JP - Giappone 15
BE - Belgio 14
ES - Italia 14
AT - Austria 13
EC - Ecuador 13
IR - Iran 11
ID - Indonesia 10
IQ - Iraq 10
PL - Polonia 10
EG - Egitto 8
PT - Portogallo 7
UZ - Uzbekistan 7
ZA - Sudafrica 6
CH - Svizzera 5
CL - Cile 5
KE - Kenya 5
MA - Marocco 5
PE - Perù 5
AU - Australia 4
CO - Colombia 4
HN - Honduras 4
LT - Lituania 4
SA - Arabia Saudita 4
JM - Giamaica 3
JO - Giordania 3
NP - Nepal 3
PK - Pakistan 3
PY - Paraguay 3
RO - Romania 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
HR - Croazia 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
MY - Malesia 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GR - Grecia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
KG - Kirghizistan 1
KI - Kiribati 1
LU - Lussemburgo 1
NG - Nigeria 1
PH - Filippine 1
QA - Qatar 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TG - Togo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.684
Salva come PNG Salva come JPEG
Città #
Southend 638
Fairfield 583
Dallas 581
Dublin 524
Ashburn 386
Chandler 324
Woodbridge 269
Santa Clara 245
Seattle 233
Singapore 223
Wilmington 203
Cambridge 200
Hong Kong 188
Beijing 180
Houston 175
Jacksonville 175
Moscow 161
Princeton 132
Ann Arbor 107
Siena 77
Hefei 58
Nanjing 50
Los Angeles 48
Helsinki 40
Ho Chi Minh City 40
São Paulo 38
The Dalles 38
Seoul 37
San Mateo 36
San Diego 35
Milan 34
New York 30
Shanghai 26
Boardman 25
London 25
Redondo Beach 25
Florence 23
Buffalo 21
Columbus 21
Paris 21
Rome 21
Hanoi 19
Dong Ket 18
Dearborn 17
Izmir 17
Brasília 15
Hebei 15
Council Bluffs 14
Tokyo 13
Brussels 12
Phoenix 12
Shenyang 12
Nuremberg 11
Bengaluru 10
Brooklyn 10
Munich 10
Rio de Janeiro 10
San Francisco 10
Warsaw 10
Bari 9
Nanchang 9
Naples 9
Palermo 9
Toronto 9
Turin 9
Belo Horizonte 8
Catania 8
Chennai 8
Frankfurt am Main 8
Jiaxing 8
Poplar 8
Tianjin 8
Vienna 8
Changsha 7
Curitiba 7
Mexico City 7
Montegranaro 7
Montreal 7
Norwalk 7
Atlanta 6
Bologna 6
Chicago 6
Guayaquil 6
Isfahan 6
Jinan 6
Johannesburg 6
Lambeth 6
Boston 5
Chur 5
Denver 5
Düsseldorf 5
Fremont 5
Kunming 5
Lappeenranta 5
Lauterbourg 5
Newark 5
Pesaro 5
Porto Alegre 5
Querétaro 5
Santos 5
Totale 6.804
Salva come PNG Salva come JPEG
Nome #
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 240
Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum 235
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 231
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 225
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 219
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 217
Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C 215
Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis 210
Screening and detecting significant liver fibrosis in patients with NAFLD: A practical approach using non-invasive tests 195
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C 184
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 181
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 173
HCV INFECTION AND CHRONIC ACTIVE HEPATITIS IN ALCOHOLICS 172
HEPATITIS-C VIRUS - A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS 171
A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy 168
Effect of α‐interferon therapy on hepatitis C viraemia in community‐acquired chronic non‐A, non‐B hepatitis: A quantitative polymerase chain reaction study 166
Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C 164
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients 161
Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience 153
EFFECT OF LACTOBACILLUS ACIDOPHILUS AND BIFIDOBACTERIUM BIFIDUM ON RECTAL CELL-KINETICS AND FECAL PH 152
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis. 152
Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?” 150
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation 149
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 147
Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis 145
Western Experience of Hepatolithiasis: Clinical Insights from a Case Series in a Tertiary Center 144
Cell renewal and cancer risk of the stomach: Analysis of cell proliferation kinetics in atrophic gastritis 144
Primary Biliary cholangitis case-finding: an italian multicenter observational study on patients with incidental finding of anti-mithocondrial antibodies 143
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 143
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels 142
Persistent hepatitis C viraemia without liver disease 138
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis 137
Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? 136
Ribavirin for chronic hepatitis C: And the mystery goes on 134
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations 133
Proctosigmoidite ulcerosa refrattaria e recidivante alla terapia topica trattata con beclometasone dipropionato orale 131
Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C 131
LONG-TERM PERSISTENCE OF IGM ANTIBODIES TO HCV IN CHRONIC HEPATITIS-C 130
Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C 129
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 129
Serological and histological aspects of hepatitis C virus infection in alcoholic patients 128
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project 127
Spleen stiffness measurements predict the risk of hepatic decompensation after direct-acting antivirals in HCV cirrhotic patients 126
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 125
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C 123
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 123
Severe acute autoimmune hepatitis after natalizumab treatment 122
What hides behind an intention-to-treat analysis? 120
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 117
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C 110
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study 110
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 105
Incidental finding of anti-mitochondrial antibody: a neglected entity needing reappraisal 103
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 100
Management of Delta Hepatitis 45 years after the discovery of HDV 99
Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction 96
Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma 94
Prospective study on the prevalence of HCV infection in consecutive adult inpatients in a hospital division of Internal Medicine in Tuscany 88
Re-treatment of patients with chronic hepatitis C in clinical practice: Results of a multicenter retrospective survey [Ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: Risultati di uno studio multicentrico retrospettivo] 87
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders 83
Whipple's disease with melaena and multiple petechial haemorrhages in duodenal mucosa 82
RECTAL CELL-PROLIFERATION AND COLON CANCER RISK IN ULCERATIVE-COLITIS 81
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 79
Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: Evidence for long-term efficacy and safety 71
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy 71
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 66
Loss and seroconversion of hepatitis B surface antigen after vaccine therapy in chronic hepatitis B patients treated with nucleoside/nucleotide analogues 66
The role of gut microbiota in chronic liver diseases 65
Prospective evaluation of aberrant p16 methylation in serum of patients before and after therapy for localized HCC 65
Trattamento della Epatite da HCV 63
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 61
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 60
VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT 58
La ribavirina nell'epatite cronica C: storia e segreti di un grande successo 56
Terapia cellulare in Epatologia 52
RIBAVIRIN PRIMING ENHANCES EFFICACY OF CHRONIC HEPATITIS C RE-TREATMENT IN PATIENTS WHO HAD NOT RESPONDED TO PREVIOUS COMBINATION THERAPY 51
Panel discussion 44
null 10
Totale 9.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021542 0 0 0 0 0 95 41 152 31 107 46 70
2021/2022750 45 68 44 54 28 26 37 37 41 78 92 200
2022/20231.021 89 90 124 158 90 237 10 78 83 4 32 26
2023/2024910 63 57 94 103 43 187 232 17 6 33 16 59
2024/20251.628 52 85 166 68 171 112 17 110 135 129 178 405
2025/20262.482 273 552 480 553 594 30 0 0 0 0 0 0
Totale 9.906